SYRE
Spyre Therapeutics, Inc.
Biotechnology
Market Cap$25.30B
5Y Perf.-60.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SYRE vs TERN
Revenue, margins, valuation, and 5-year total return — side by side.
TERN
Terns Pharmaceuticals, Inc.
Biotechnology
Market Cap$4.63B
5Y Perf.+133.7%
SYRE vs TERN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SYRE | TERN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $25.30B | $4.63B |
| Revenue (TTM) | $90M | $0.00 |
| Net Income (TTM) | $-179M | $-94M |
| Operating Margin | -256.0% | — |
| Total Debt | $0.00 | $1M |
| Cash & Equiv. | $86M | $161M |
SYRE vs TERN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SYRE
TERN
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| Spyre Therapeutics,… (SYRE) | 100 | 39.2 | -60.8% |
| Terns Pharmaceutica… (TERN) | 100 | 233.7 | +133.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SYRE vs TERN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TERN leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Spyre Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
SYRE
Spyre Therapeutics, Inc.
The Growth Play
SYRE is the clearest fit if your priority is growth exposure.
- EPS growth 37.7%
- 8.6% revenue growth vs TERN's -7.6%
- -27.8% ROA vs TERN's -28.5%, ROIC -29.7% vs -42.2%
Best for: growth exposure
TERN
Terns Pharmaceuticals, Inc.
The Income Pick
TERN carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.39
- 187.9% 10Y total return vs SYRE's -66.8%
- Lower volatility, beta 0.39, Low D/E 0.4%, current ratio 23.14x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SYRE | 8.6% revenue growth vs TERN's -7.6% |
| Quality / Margins | TERN | 3.7% margin vs SYRE's -198.3% |
| Stability / Safety | TERN | Beta 0.39 vs SYRE's 2.06 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TERN | +16.5% vs SYRE's +475.1% |
| Efficiency (ROA) | SYRE | -27.8% ROA vs TERN's -28.5%, ROIC -29.7% vs -42.2% |
SYRE vs TERN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
Segment breakdown not available.
SYRE vs TERN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTERNLAGGINGSYRE
SYRESpyre Therapeutics, I…
1leads
TERNTerns Pharmaceuticals…
3leads
6 Total Categories
CATEGORYLEADERvs SYREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TERN1/1
Valuation MetricsMultiples, price ratios, and targets
TERN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SYRE4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
TERN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TERN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SYRE and TERN operate at a comparable scale, with $90M and $0 in trailing revenue.
| Metric | SYRESpyre Therapeutic… | TERNTerns Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $90M | $0 |
| EBITDAEarnings before interest/tax | -$171M | -$108M |
| Net IncomeAfter-tax profit | -$179M | -$94M |
| Free Cash FlowCash after capex | -$186M | -$78M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | -2.6% | — |
| Net MarginNet income ÷ Revenue | -198.3% | — |
| FCF MarginFCF ÷ Revenue | -2.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -4.7% | +3.6% |
TERN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
TERN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | SYRESpyre Therapeutic… | TERNTerns Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $25.3B | $4.6B |
| Enterprise ValueMkt cap + debt − cash | $25.2B | $4.5B |
| Trailing P/EPrice ÷ TTM EPS | -36.92x | -47.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 35.37x | 12.17x |
| Price / FCFMarket cap ÷ FCF | — | — |
TERN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
SYRE leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
TERN delivers a -30.0% return on equity — every $100 of shareholder capital generates $-30 in annual profit, vs $-31 for SYRE. On the Piotroski fundamental quality scale (0–9), TERN scores 3/9 vs SYRE's 2/9, reflecting mixed financial health.
| Metric | SYRESpyre Therapeutic… | TERNTerns Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -31.2% | -30.0% |
| ROA (TTM)Return on assets | -27.8% | -28.5% |
| ROICReturn on invested capital | -29.7% | -42.2% |
| ROCEReturn on capital employed | -32.9% | -33.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$86M | -$160M |
| Cash & Equiv.Liquid assets | $86M | $161M |
| Total DebtShort + long-term debt | $0 | $1M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
SYRE leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — SYRE and TERN each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TERN five years ago would be worth $31,859 today (with dividends reinvested), compared to $4,039 for SYRE. Over the past 12 months, TERN leads with a +1647.5% total return vs SYRE's +475.1%. The 3-year compound annual growth rate (CAGR) favors SYRE at 164.5% vs TERN's 59.1% — a key indicator of consistent wealth creation.
| Metric | SYRESpyre Therapeutic… | TERNTerns Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | +139.0% | +32.0% |
| 1-Year ReturnPast 12 months | +475.1% | +1647.5% |
| 3-Year ReturnCumulative with dividends | +1750.6% | +302.7% |
| 5-Year ReturnCumulative with dividends | -59.6% | +218.6% |
| 10-Year ReturnCumulative with dividends | -66.8% | +187.9% |
| CAGR (3Y)Annualised 3-year return | +164.5% | +59.1% |
Evenly matched — SYRE and TERN each lead in 3 of 6 comparable metrics.
Risk & Volatility
TERN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TERN is the less volatile stock with a 0.39 beta — it tends to amplify market swings less than SYRE's 2.06 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TERN currently trades 99.6% from its 52-week high vs SYRE's 96.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SYRESpyre Therapeutic… | TERNTerns Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.06x | 0.39x |
| 52-Week HighHighest price in past year | $76.00 | $53.18 |
| 52-Week LowLowest price in past year | $12.29 | $2.66 |
| % of 52W HighCurrent price vs 52-week peak | +96.2% | +99.6% |
| RSI (14)Momentum oscillator 0–100 | 65.2 | 74.2 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 6.7M |
TERN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SYRE as "Buy" and TERN as "Buy". Consensus price targets imply 12.0% upside for SYRE (target: $82) vs 4.9% for TERN (target: $56).
| Metric | SYRESpyre Therapeutic… | TERNTerns Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $81.90 | $55.56 |
| # AnalystsCovering analysts | 10 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TERN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). SYRE leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallTerns Pharmaceuticals, Inc. (TERN)Leads 3 of 6 categories
Loading custom metrics...
SYRE vs TERN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SYRE or TERN a better buy right now?
Analysts rate Spyre Therapeutics, Inc.
(SYRE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SYRE or TERN?
Over the past 5 years, Terns Pharmaceuticals, Inc.
(TERN) delivered a total return of +218. 6%, compared to -59. 6% for Spyre Therapeutics, Inc. (SYRE). Over 10 years, the gap is even starker: TERN returned +187. 9% versus SYRE's -66. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SYRE or TERN?
By beta (market sensitivity over 5 years), Terns Pharmaceuticals, Inc.
(TERN) is the lower-risk stock at 0. 39β versus Spyre Therapeutics, Inc. 's 2. 06β — meaning SYRE is approximately 421% more volatile than TERN relative to the S&P 500.
04Which is growing faster — SYRE or TERN?
On earnings-per-share growth, the picture is similar: Spyre Therapeutics, Inc.
grew EPS 37. 7% year-over-year, compared to 11. 8% for Terns Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SYRE or TERN?
Terns Pharmaceuticals, Inc.
(TERN) is the more profitable company, earning 0. 0% net margin versus -198. 3% for Spyre Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TERN leads at 0. 0% versus -256. 0% for SYRE. At the gross margin level — before operating expenses — SYRE leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SYRE or TERN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SYRE or TERN better for a retirement portfolio?
For long-horizon retirement investors, Terns Pharmaceuticals, Inc.
(TERN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), +187. 9% 10Y return). Spyre Therapeutics, Inc. (SYRE) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TERN: +187. 9%, SYRE: -66. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SYRE and TERN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.